Zacks Research Upgrades Sensei Biotherapeutics (NASDAQ:SNSE) to “Hold”

Sensei Biotherapeutics (NASDAQ:SNSE) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Other research analysts also recently issued reports about the company. Wall Street Zen upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Saturday, December 27th. Leerink Partners started coverage on Sensei Biotherapeutics in a research note on Monday. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics currently has an average rating of “Hold” and an average target price of $40.00.

Sensei Biotherapeutics Trading Up 4.2%

Shares of NASDAQ:SNSE opened at $31.64 on Tuesday. The stock has a 50 day moving average of $28.78 and a 200 day moving average of $16.43. The company has a market cap of $42.40 million, a PE ratio of -1.90 and a beta of -0.10. Sensei Biotherapeutics has a 12-month low of $5.25 and a 12-month high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings data on Monday, March 30th. The company reported ($3.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.81) by $1.07. Equities research analysts predict that Sensei Biotherapeutics will post -2.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.